How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

128,667 results for

Demulen 1/35

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

81. Patent foramen ovale with complex anatomy: Comparison of two different devices (Amplatzer Septal Occluder device and Amplatzer PFO Occluder device 30/35). (Abstract)

analysis.Comparing group I and group II, there weren't complications during the procedures. Two patients of group II were lost at follow-up. At last follow-up, 1 pt of group I (3%) and 10 pts of group II (32.3%) had a residual shunt (p < 0.01). 7 of 10 pts of group II and the only 1 of group I with residual shunt underwent a complete closure by Amplatzer™ Vascular Plug (AVP) devices.ASO devices and A-PFO 30/35 devices are both safe to close complex PFO; but A-PFO 30/35 is associated with a more incidence (...) Patent foramen ovale with complex anatomy: Comparison of two different devices (Amplatzer Septal Occluder device and Amplatzer PFO Occluder device 30/35). Patent foramen ovale (PFO) closure after a cryptogenic cerebral ischemic event is a routinely procedure. The most used device is Amplatzer™ PFO Occluder 25 mm, but PFOs with complex anatomy require larger device for closure. We compared Amplatzer™ Septal Occluder (ASO) device versus Amplatzer™ PFO Occluder 30 or 35 mm (A-PFO 30/35) about

2018 International journal of cardiology

82. Immunogenicity and Safety of NBP607-QIV Compared to Agrippal in Children Aged 6 to 35 Months

for the the prevention of influenza disease. Total of 675 subjects or above (450 subjects for NBP607-QIV arm and 225 subjects for Agrippal arm) of 6 to 35 months of age are enrolled. Each subject is administered with single or two doses of vaccines depending on previous vaccination history, and randomly assigned in 2:1 ratio. Stratified randomization for trial site and age strata is used to achieve the balance of treatment assignment. Total of three or five visits are scheduled depeding on dosing schedule (...) the study research staff using the contacts provided below. For general information, Layout table for eligibility information Ages Eligible for Study: 6 Months to 35 Months (Child) Sexes Eligible for Study: All Accepts Healthy Volunteers: Yes Criteria Inclusion Criteria: Children aged 6 to 35 months Those who were normal gestational age at birth (for children aged 6 months to <1 year) Those who have provided written informed consent to study participation and compliance with study instructions after

2018 Clinical Trials

83. Safety and Immunogenicity of a Full-Dose Split-Virion Inactivated Quadrivalent Influenza Vaccine in Healthy Children 6 to 35 Months of Age: A Randomized Controlled Clinical Trial. Full Text available with Trip Pro

, we compare the safety and immunogenicity of full and half doses of quadrivalent, split-virion, inactivated influenza vaccine (IIV4) in children 6-35 months of age.In this phase IV, randomized, observer-blinded, multi-center study, healthy children 6-35 months of age were randomized 1:1 to be vaccinated with a half or full dose of IIV4 (NCT02915302). The primary objective was to demonstrate that the rate of any fever (≥38.0°C) up to 7 days after a full dose of IIV4 was noninferior to the rate (...) Safety and Immunogenicity of a Full-Dose Split-Virion Inactivated Quadrivalent Influenza Vaccine in Healthy Children 6 to 35 Months of Age: A Randomized Controlled Clinical Trial. For children <3 years of age, a half dose of inactivated influenza vaccine (7.5 μg hemagglutinin per strain) has been used for more than 30 years, but several studies indicate that a full dose (15 μg hemagglutinin per strain) can be used in this population without increasing the rate of fever or other reactions. Here

2018 Pediatric Infectious Dsease Journal Controlled trial quality: predicted high

84. The Effects of Laparoscopic Sleeve Gastrectomy with Duodenojejunal Bypass on Japanese Patients with BMI &lt; 35 kg/m<sup>2</sup> on Type 2 Diabetes Mellitus and the Prediction of Successful Glycemic Control. (Abstract)

study, we examined the clinical effects of LSG-DJB on mildly obese patients (body mass index (BMI) < 35 kg/m2) with type 2 diabetes mellitus (T2DM) and analyzed factors contributing to the successful postoperative glycemic control.Seventy-two consecutive Japanese patients with T2DM with a BMI of < 35 kg/m2 who underwent LSG-DJB in a single institution from September 2007 to March 2015 were included for the study. Weight loss, safety, and the impact on T2DM and metabolic syndrome were examined at 1 (...) The Effects of Laparoscopic Sleeve Gastrectomy with Duodenojejunal Bypass on Japanese Patients with BMI < 35 kg/m2 on Type 2 Diabetes Mellitus and the Prediction of Successful Glycemic Control. Laparoscopic sleeve gastrectomy with duodenojejunal bypass (LSG-DJB) is a combination of sleeve gastrectomy and proximal intestinal bypass through duodenal exclusion. This technique has shown excellent weight loss and anti-diabetic effects in severely obese patients. In this retrospective

2018 Obesity Surgery

85. Safety, Tolerability, and Efficacy of the Human Cytomegalovirus Vaccine (V160) in Healthy Women 16 to 35 Years of Age (V160-002)

seronegative women 16 to 35 years of age. Participants will receive blinded V160 on Day 1, Month 2, and Month 6 (3-dose regimen), V160 on Day 1 and Month 6 and placebo at Month 2 (2-dose regimen), or placebo on Day 1, Month 2, and Month 6, and will be followed to approximately Month 36. The primary hypothesis of the study is that administration of a 3-dose regimen of V160 will reduce the incidence of primary CMV infection compared to placebo. Condition or disease Intervention/treatment Phase (...) : 16 Years to 35 Years (Child, Adult) Sexes Eligible for Study: Female Accepts Healthy Volunteers: Yes Criteria Inclusion Criteria: Healthy based on medical history and physical examination Serologically confirmed to be CMV seronegative Have direct exposure to young children (≤5 years of age) at home or occupationally Of child bearing potential Agrees to avoid becoming pregnant during the 6-month treatment period and for at least 4 weeks after the last dose of study drug by either 1) practicing

2018 Clinical Trials

86. Descriptive Study of Brain Velocity in Transcranial Doppler in Newborns Over 35 Weeks of Gestational Age in the Maternity Ward

Descriptive Study of Brain Velocity in Transcranial Doppler in Newborns Over 35 Weeks of Gestational Age in the Maternity Ward Descriptive Study of Brain Velocity in Transcranial Doppler in Newborns Over 35 Weeks of Gestational Age in the Maternity Ward - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached (...) the maximum number of saved studies (100). Please remove one or more studies before adding more. Descriptive Study of Brain Velocity in Transcranial Doppler in Newborns Over 35 Weeks of Gestational Age in the Maternity Ward (VELOCITE) The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. of clinical studies and talk to your health care provider before participating

2018 Clinical Trials

87. Efficacy and Safety of AD-35 in Treatment of Subjects With Mild to Moderate Alzheimer's Disease

treatment followed by a second 6 months of open-label treatment to subjects with mild to moderate AD. Condition or disease Intervention/treatment Phase Alzheimer Disease, Early Onset Drug: AD-35 60mg group Drug: AD-35 90mg group Drug: Placebo group Phase 2 Detailed Description: Approximately 88 subjects are planned to be enrolled for the entire study. Initially, approximately 30 subjects will be randomized via a centralized interactive response technology (IRT) in a 1:2 ratio (ie, approximately 10 (...) subjects will be enrolled and will be randomized in a 1:1:3 ratio to receive placebo, 60 mg AD-35, and 90 mg AD-35, respectively.After the first 6 months of double-blind treatment, subjects on active study drug will remain on the current dose, and subjects assigned to placebo will receive 60 mg and 90 mg AD-35 in a 1:2 ratio, respectively, for an additional 6 months of open-label treatment. Study Design Go to Layout table for study information Study Type : Interventional (Clinical Trial) Estimated

2018 Clinical Trials

88. Integrating HDAd5/35++ Vectors as a New Platform for HSC Gene Therapy of Hemoglobinopathies Full Text available with Trip Pro

Integrating HDAd5/35++ Vectors as a New Platform for HSC Gene Therapy of Hemoglobinopathies We generated an integrating, CD46-targeted, helper-dependent adenovirus HDAd5/35++ vector system for hematopoietic stem cell (HSC) gene therapy. The ∼12-kb transgene cassette included a β-globin locus control region (LCR)/promoter driven human γ-globin gene and an elongation factor alpha-1 (EF1α)-mgmtP140K expression cassette, which allows for drug-controlled increase of γ-globin-expressing erythrocytes (...) was performed with peripheral blood CD34+ cells from mobilized donors. 10 weeks after transplantation of transduced cells, human cells were harvested from the bone marrow and differentiated ex vivo into erythroid cells. Erythroid cells expressed γ-globin at a level of 20% of adult α-globin. Our studies suggest that HDAd35++ vectors allow for efficient transduction of long-term repopulating HSCs and high-level, almost pancellular γ-globin expression in erythrocytes. Furthermore, our HDAd5/35++ vectors have

2018 Molecular therapy. Methods & clinical development

89. Epidemiologic Factors, Clinical Presentation, Causes, and Outcomes of Liver Abscess: A 35-Year Olmsted County Study Full Text available with Trip Pro

Epidemiologic Factors, Clinical Presentation, Causes, and Outcomes of Liver Abscess: A 35-Year Olmsted County Study To report the changing incidence, clinical presentation, microbiologic spectrum, and outcomes of pyogenic liver abscess (PLA) in Olmsted County, Minnesota, over the past 35 years.The Rochester Epidemiology Project was used to identify residents with PLA from January 1, 1980, through December 31, 2014. The study included all patients older than 18 years, with the diagnosis of PLA (...) confirmed through radiographic review and microbiologic cultures.In total, 72 patients received a diagnosis of PLA from 1980 through 2014. The age-adjusted incidence for men was 3.92 cases per 100,000 person-years (95% CI, 2.76-5.09 cases per 100,000 person-years) compared with 1.87 cases per 100,000 person-years (95% CI, 1.15-2.59 cases per 100,000 person-years) for women. Incidence was higher in the period from January 1, 2001, through December 31, 2014, than in the period from January 1, 1980

2018 Mayo Clinic Proceedings. Innovations, Quality & Outcomes

90. Correction for Johnson et al., “Complete Genome Sequences for 35 Biothreat Assay-Relevant Bacillus Species” Full Text available with Trip Pro

Correction for Johnson et al., “Complete Genome Sequences for 35 Biothreat Assay-Relevant Bacillus Species” 29348328 2018 01 30 2169-8287 6 3 2018 Jan 18 Genome announcements Genome Announc Correction for Johnson et al., "Complete Genome Sequences for 35 Biothreat Assay-Relevant Bacillus Species". e01144-17 10.1128/genomeA.01144-17 Johnson Shannon L SL http://orcid.org/0000-0002-3972-9208 Los Alamos National Laboratory (LANL), Los Alamos, New Mexico, USA shannonj@lanl.gov. Daligault (...) Genome Announc 101595808 Genome Announc. 2015 Apr 30;3(2): 25931591 2018 1 20 6 0 2018 1 20 6 0 2018 1 20 6 0 epublish 29348328 6/3/e01144-17 10.1128/genomeA.01144-17 PMC5773713

2018 Genome Announcements

91. Comparison of the anti-apoptotic effects of 15- and 35-minute suspended moxibustion after focal cerebral ischemia/reperfusion injury Full Text available with Trip Pro

Comparison of the anti-apoptotic effects of 15- and 35-minute suspended moxibustion after focal cerebral ischemia/reperfusion injury Heat-sensitive suspended moxibustion has a neuroprotective effect against focal cerebral ischemia/reperfusion injury, but the underlying mechanisms remain unclear. The duration of heat-sensitive suspended moxibustion (usually from 30 minutes to 1 hour) is longer than traditional suspended moxibustion (usually 15 minutes). However, the effects of 15- and 35-minute (...) suspended moxibustion in rats with cerebral ischemia/reperfusion injury are poorly understood. In this study, we performed 15- or 35-minute suspended moxibustion at acupoint Dazhui (GV14) in an adult rat model of focal cerebral ischemia/reperfusion injury. Infarct volume was evaluated with the 2,3,5-triphenyltetrazolium chloride assay. Histopathological changes and neuronal apoptosis at the injury site were assessed by hematoxylin-eosin staining and terminal deoxynucleotidyl transferase dUTP nick end

2018 Neural Regeneration Research

92. Neuroprotective effect of a new photobiomodulation technique against Aβ25–35 peptide–induced toxicity in mice: Novel hypothesis for therapeutic approach of Alzheimer's disease suggested Full Text available with Trip Pro

on the top of the head or the center of abdomen or both.RGn500 daily application for 10 min produced a neuroprotective effect on the neurotoxic effects of amyloid β 25-35 peptide injection when this type of photobiomodulation was applied both on the head and on the abdomen. Protection was demonstrated by memory restoration and on the normalization of key markers of AD (amyloid β 1-42, pTau), oxidative stress (lipid peroxidation), apoptosis (Bax/Bcl2) and neuroinflammation.RGn500 displays therapeutic (...) Neuroprotective effect of a new photobiomodulation technique against Aβ25–35 peptide–induced toxicity in mice: Novel hypothesis for therapeutic approach of Alzheimer's disease suggested Photobiomodulation was assessed as a novel treatment of Alzheimer's disease (AD) by the use of a new device RGn500 combining photonic and magnetic emissions in a mouse model of AD.Following the injection of amyloid β 25-35 peptide in male Swiss mice, RGn500 was applied once a day for 7 days either

2018 Alzheimer's & dementia : translational research & clinical interventions

93. Nanostructural Differentiation and Toxicity of Amyloid-β25-35 Aggregates Ensue from Distinct Secondary Conformation Full Text available with Trip Pro

. In this work, Aβ25-35, a fragment of amyloid β(1-42) (Aβ42), was selected to investigate the correlation between secondary structures and toxicity of amyloid fibrils. Furthermore, each aggregation assemblies show different cell membrane disruption and cytotoxicity. The structural analysis of amyloid aggregates originated from different secondary structure motifs is helpful to understand the mechanism of peptides/cell interactions in the pathogenesis of amyloid diseases. (...) Nanostructural Differentiation and Toxicity of Amyloid-β25-35 Aggregates Ensue from Distinct Secondary Conformation Amyloid nanostructures are originated from protein misfolding and aberrant aggregation, which is associated with the pathogenesis of many types of degenerative diseases, such as Alzheimer's disease (AD), Parkinson's disease (PD) and Huntington's disease. The secondary conformation of peptides is of a fundamental importance for aggregation and toxicity of amyloid peptides

2018 Scientific reports

94. Genotype–phenotype investigation of 35 patients from 11 unrelated families with camptodactyly–arthropathy–coxa vara–pericarditis (CACP) syndrome Full Text available with Trip Pro

Genotype–phenotype investigation of 35 patients from 11 unrelated families with camptodactyly–arthropathy–coxa vara–pericarditis (CACP) syndrome The camptodactyly-arthropathy-coxa vara-pericarditis syndrome (CACP) is a rare autosomal recessive condition characterized by camptodactyly, noninflammatory arthropathy, coxa vara, and pericarditis. CACP is caused by mutations in the proteoglycan 4 (PRG4) gene, which encodes a lubricating glycoprotein present in the synovial fluid (...) and at the surface of articular cartilage.In the present study, we compared the clinical and molecular findings of CACP syndrome in 35 patients from 11 unrelated families. In 28 patients, whole exome sequencing was used to investigate genomic variations.We found that camptodactyly of hands was the first symptom presented by most patients. Swelling of wrists, knees, and elbows began before 4 years of age, while the age of joint involvement was variable. Patients reported an increased pain level after the age

2018 Molecular Genetics & Genomic Medicine

95. GCY-35/GCY-36—TAX-2/TAX-4 Signalling in O2 Sensory Neurons Mediates Acute Functional Ethanol Tolerance in Caenorhabditis elegans Full Text available with Trip Pro

and even intoxication with increasing concentrations. Animals develop tolerance to ethanol. However, the underlying mechanisms are not well understood. In Caenorhabditis elegans, NPR-1 negatively regulates the development of acute tolerance to ethanol. Here, using in vivo Ca2+ imaging, behavioural tests and chemogenetic manipulation, we show that the soluble guanylate cyclase complex GCY-35/GCY-36-TAX-2/TAX-4 signalling pathway in O2 sensory neurons positively regulates acute functional tolerance (...) GCY-35/GCY-36—TAX-2/TAX-4 Signalling in O2 Sensory Neurons Mediates Acute Functional Ethanol Tolerance in Caenorhabditis elegans Ethanol is a widely used beverage and abused drug. Alcoholism causes severe damage to human health and creates serious social problems. Understanding the mechanisms underlying ethanol actions is important for the development of effective therapies. Alcohol has a wide spectrum of effects on physiological activities and behaviours, from sensitization to sedation

2018 Scientific reports

96. Induction therapy with paclitaxel and bevacizumab followed by switch maintenance therapy with eribulin in Japanese patients with HER2-negative metastatic breast cancer: a multicenter, collaborative, open-label, phase II clinical study for the SBCCSG 35 in Full Text available with Trip Pro

Induction therapy with paclitaxel and bevacizumab followed by switch maintenance therapy with eribulin in Japanese patients with HER2-negative metastatic breast cancer: a multicenter, collaborative, open-label, phase II clinical study for the SBCCSG 35 in To examine the efficacy and safety of induction therapy with paclitaxel and bevacizumab followed by switch maintenance therapy with eribulin (ISMT) in Japanese patients with HER2-negative metastatic breast cancer (MBC).Patients, who had (...) previously undergone a maximum of 2 regimens of chemotherapy, received 3 cycles of induction therapy with paclitaxel (90 mg/m2 intravenously on days 1, 8, and 15 followed by 1-week drug holiday) and bevacizumab (10 mg/kg intravenously after the completion of paclitaxel administration on days 1 and 15). Patients who had complete response, partial response, or stable disease underwent switch maintenance therapy with eribulin (1.4 mg/m2 intravenously on days 1 and 8 followed by 1-week drug holiday

2018 BMC Cancer

97. Screening for pre-eclampsia at 35-37 weeks' gestation. Full Text available with Trip Pro

Screening for pre-eclampsia at 35-37 weeks' gestation. To examine the performance of screening for pre-eclampsia (PE) at 35-37 weeks' gestation by maternal factors and combinations of mean arterial pressure (MAP), uterine artery pulsatility index (UtA-PI), serum placental growth factor (PlGF) and serum soluble fms-like tyrosine kinase-1 (sFlt-1).This was a prospective observational study in women with singleton pregnancy attending for an ultrasound scan at 35 + 0 to 36 + 6 weeks as part (...) was not improved by the addition of UtA-PI. The performance of screening depended on the racial origin of the women; in screening by a combination of maternal factors, MAP, PlGF and sFlt-1 and use of the risk cut-off of 1 in 20, the detection rate and screen-positive rate were 66% and 9.5%, respectively, for Caucasian women and 88% and 18% for those of Afro-Caribbean racial origin.Screening by maternal factors and biomarkers at 35-37 weeks' gestation can identify a high proportion of pregnancies that develop

2018 Ultrasound in Obstetrics and Gynecology

98. Response to comment on: Thomson et al. Muscle strength gains during resistance exercise training are attenuated with soy compared with dairy or usual protein intake in older adults: A randomized controlled trial. Clinical Nutrition 35:27-33, 2016. (Abstract)

, Australia. Noakes Manny M Commonwealth Scientific and Industrial Research Organisation, Food and Nutrition Flagship, Adelaide, South Australia, Australia. Buckley Jonathan D JD Alliance for Research in Exercise, Nutrition and Activity (ARENA), Sansom Institute for Health Research, University of South Australia, Adelaide, South Australia, Australia. Electronic address: jon.buckley@unisa.edu.au. eng Letter Comment 2016 07 20 England Clin Nutr 8309603 0261-5614 IM Clin Nutr. 2016 Feb;35(1):27-33 25702958 (...) Response to comment on: Thomson et al. Muscle strength gains during resistance exercise training are attenuated with soy compared with dairy or usual protein intake in older adults: A randomized controlled trial. Clinical Nutrition 35:27-33, 2016. 27472928 2018 08 10 2018 12 02 1532-1983 35 6 2016 12 Clinical nutrition (Edinburgh, Scotland) Clin Nutr Response to comment on: Thomson et al. Muscle strength gains during resistance exercise training are attenuated with soy compared with dairy

2018 Clinical nutrition (Edinburgh, Scotland) Controlled trial quality: uncertain

99. Risk of Cesarean Section in Primiparous Women Over 35 Years of Age.

Procedure: Cesarean section Procedure: No cesarean section Study Design Go to Layout table for study information Study Type : Observational Actual Enrollment : 572 participants Observational Model: Cohort Time Perspective: Retrospective Official Title: Risk of Cesarean Section and Perinatal Complications in Primiparous Women Over 35 Years of Age. A Retrospective Cohort Study. Actual Study Start Date : April 1, 2017 Actual Primary Completion Date : January 1, 2018 Actual Study Completion Date : February (...) Risk of Cesarean Section in Primiparous Women Over 35 Years of Age. Risk of Cesarean Section in Primiparous Women Over 35 Years of Age. - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Risk of Cesarean

2018 Clinical Trials

100. The clinical potential of IL-12/IL-35 in treating chemotherapy drug-induced cardiac injury – Authors' reply Full Text available with Trip Pro

23050732 Hypertension. 2009 Sep;54(3):619-24 19620507 Hypertension. 2017 Oct;70(4):839-845 28847894 Immunol Rev. 2018 Jan;281(1):179-190 29247987 EBioMedicine. 2018 Sep;35:2-3 30143465 Atherosclerosis. 2015 Oct;242(2):506-14 26298743 (...) The clinical potential of IL-12/IL-35 in treating chemotherapy drug-induced cardiac injury – Authors' reply 30174280 2018 11 14 2352-3964 35 2018 Sep EBioMedicine EBioMedicine The clinical potential of IL-12/IL-35 in treating chemotherapy drug-induced cardiac injury - Authors' reply. 4-5 S2352-3964(18)30341-4 10.1016/j.ebiom.2018.08.049 Ye Jing J Emergency & Critical Care Center, Beijing Anzhen Hospital, Capital Medical University, Beijing Institute of Heart, Lung, and Blood Vessel Diseases

2018 EBioMedicine

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>